FIH-IO
Financiado
Development of a first-in-class inhibitor of FIH for cancer immunotherapy
We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the f...
We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology.
The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation. Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2022-05-12
Fecha Fin: 2023-11-30
Fecha Fin: 2023-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-30
HORIZON EUROPE
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Líder del proyecto
ASOCIACION CENTRO DE INVESTIGACION COOPERATIV...
No se ha especificado una descripción o un objeto social para esta compañía.
